Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial

Inge Sutanto, Ayleen Kosasih, Iqbal R F Elyazar, Deddy R Simanjuntak, Tri A Larasati, M Sopiyudin Dahlan, Isra Wahid, Ivo Mueller, Cristian Koepfli, Rita Kusriastuti, Asik Surya, Ferdinand J Laihad, William A Hawley, Frank H Collins, J Kevin Baird, Neil F Lobo, Inge Sutanto, Ayleen Kosasih, Iqbal R F Elyazar, Deddy R Simanjuntak, Tri A Larasati, M Sopiyudin Dahlan, Isra Wahid, Ivo Mueller, Cristian Koepfli, Rita Kusriastuti, Asik Surya, Ferdinand J Laihad, William A Hawley, Frank H Collins, J Kevin Baird, Neil F Lobo

Abstract

Background: Mass screening and treatment (MST) aims to reduce malaria risk in communities by identifying and treating infected persons without regard to illness.

Methods: A cluster-randomized trial evaluated malaria incidence with and without MST. Clusters were randomized to 3, 2, or no MST interventions: MST3, 6 clusters (156 households/670 individuals); MST2, 5 clusters (89 households/423 individuals); and MST0, 5 clusters (174 households/777 individuals). All clusters completed the study with 14 residents withdrawing. In a cohort of 324 schoolchildren (MST3, n = 124; MST2, n = 57; MST0, n = 143) negative by microscopy at enrollment, we evaluated the incidence density of malaria during 3 months of MST and 3 months following. The MST intervention involved community-wide expert malaria microscopic screening and standard therapy with dihydroartemisinin-piperaquine and primaquine for glucose-6 phosphate dehydrogenase-normal subjects. All blood examinations included polymerase chain reaction assays, which did not guide on-site treatment.

Results: The risk ratios for incidence density of microscopically patent malaria in MST3 or MST2 relative to that in MST0 clusters were 1.00 (95% confidence interval [CI], .53-1.91) and 1.22 (95% CI, .42-3.55), respectively. Similar results were obtained with molecular analysis and species-specific (P. falciparum and P. vivax) infections. Microscopically subpatent, untreated infections accounted for 72% of those infected.

Conclusions: Two or 3 rounds of MST within 3 months did not impact the force of anopheline mosquito-borne infection in these communities. The high rate of untreated microscopically subpatent infections likely explains the observed poor impact.

Clinical trials registration: NCT01878357.

Figures

Figure 1.
Figure 1.
Map of the study site. Abbreviation: MST, mass screening and treatment.
Figure 2.
Figure 2.
Trial profile. Abbreviations: GPS, Global Positioning System; MST, mass screening and treatment.
Figure 3.
Figure 3.
Malaria prevalence by microscopy and polymerase chain reaction (PCR), and Plasmodium falciparum gametocyte rate by microscopy at the cluster (A–D) and individual levels (E–H). Cluster level showed significant decrease of P. falciparum infections based on microscopic and PCR examinations at the last survey (B). Individual level demonstrated this change with PCR (F). Similarly, gametocytes of P. falciparum that was detected by microscopy demonstrated significant decrease in cluster level (C). In Plasmodium vivax infections, neither change was detected in the cluster and individual levels (D and H). The χ2 test was used for individual level, and generalizing estimating equations was used for cluster level. Abbreviation: MST, mass screening and treatment.
Figure 4.
Figure 4.
Microscopic (A–C) and polymerase chain reaction (D–F) based individual malaria incidence density of schoolchildren in all arms within 6 months. No significant difference of incidence density in all malaria, Plasmodium falciparum, and Plasmodium vivax infections between arms. Hazard ratios were estimated using Cox regression analysis. Abbreviations: CI, confidence interval; HR, hazard ratio; MST, mass screening and treatment.

References

    1. World Health Organization. Global plan for artemisinin resistance containment. Geneva, Switzerland: WHO, 2011.
    1. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J 2008; 7(Suppl 1):S8.
    1. Ogutu B, Tiono AB, Makanga M, et al. . Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?Malar J 2010; 9:30.
    1. John CC. Primaquine plus artemisinin combination therapy for reduction of malaria transmission: promise and risk. BMC Med 2016; 14:65.
    1. Tiono AB, Ouédraogo A, Ogutu B, et al. . A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J 2013; 12:79.
    1. Halliday KE, Okello G, Turner EL, et al. . Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. PLoS Med 2014; 11:e1001594.
    1. von Seidlein L. The failure of screening and treating as a malaria elimination strategy. PLoS Med 2014; 11:e1001595.
    1. Cook J, Xu W, Msellem M, et al. . Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 2015; 211:1476–83.
    1. Larsen DA, Bennett A, Silumbe K, et al. . Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg 2015; 92:913–21.
    1. Scott CA, Yeshiwondim AK, Serda B, et al. . Mass testing and treatment for malaria in low transmission areas in Amhara Region, Ethiopia. Malar J 2016; 15:305.
    1. Tiono AB, Guelbeogo MW, Sagnon NF, et al. . Dynamics of malaria transmission and susceptibility to clinical malaria episodes following treatment of Plasmodium falciparum asymptomatic carriers: results of a cluster-randomized study of community-wide screening and treatment, and a parallel entomology study. BMC Infect Dis 2013; 13:535.
    1. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 2002; 15:66–78.
    1. Alemu A, Fuehrer HP, Getnet G, Kassu A, Getie S, Noedl H. Comparison of Giemsa microscopy with nested PCR for the diagnosis of malaria in North Gondar, north-west Ethiopia. Malar J 2014; 13:174.
    1. Aydin-Schmidt B, Morris U, Ding XC, et al. . Field evaluation of a high throughput loop mediated isothermal amplification test for the detection of asymptomatic Plasmodium infections in Zanzibar. PLoS One 2017; 12:e0169037.
    1. Battle KE, Guerra CA, Golding N, et al. . Global database of matched Plasmodium falciparum and P. vivax incidence and prevalence records from 1985–2013. Sci Data 2015; 2:150012.
    1. Cheng Q, Cunningham J, Gatton ML. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis 2015; 9:e3413.
    1. Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ. A systematic review of sub-microscopic Plasmodium vivax infection. Malar J 2015; 14:360.
    1. Ernst KC, Adoka SO, Kowuor DO, Wilson ML, John CC. Malaria hotspot areas in a highland Kenya site are consistent in epidemic and non-epidemic years and are associated with ecological factors. Malar J 2006; 5:78.
    1. Chowell G, Munayco CV, Escalante AA, McKenzie FE. The spatial and temporal patterns of falciparum and vivax malaria in Perú: 1994–2006. Malar J 2009; 8:142.
    1. Rosas-Aguirre A, Ponce OJ, Carrasco-Escobar G, et al. . Plasmodium vivax malaria at households: spatial clustering and risk factors in a low endemicity urban area of the northwestern Peruvian coast. Malar J 2015; 14:176.
    1. Hay SI, Smith DL, Snow RW. Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect Dis 2008; 8:369–78.
    1. Kementrian Kesehatan Republic of Indonesia. Pedoman tata laksana malaria. Jakarta: Kementrian Kesehatan Republik Indonesia, 2012.
    1. Mangold KA, Manson RU, Koay ES, et al. . Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol 2005; 43:2435–40.
    1. Donner A, Klar N. Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol 1994; 140:279–89; discussion 300–1.
    1. Bennett S, Parpia T, Hayes R, Cousens S. Methods for the analysis of incidence rates in cluster randomized trials. Int J Epidemiol 2002; 31:839–46.
    1. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004; 48:2787–92.
    1. Galappaththy GNL, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 2013; CD004389.
    1. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986; 292:746–50.
    1. Ranstam J. Why the P-value culture is bad and confidence intervals a better alternative. Osteoarthritis Cartilage 2012; 20:805–8.
    1. Slater HC, Ross A, Ouédraogo AL, et al. . Assessing the impact of next-generation rapid diagnostic tests on Plasmodium falciparum malaria elimination strategies. Nature 2015; 528:S94–101.
    1. Das S, Jang IK, Barney B, et al. . Performance of a high-sensitivity rapid diagnostic test for Plasmodium falciparum malaria in asymptomatic individuals from Uganda and Myanmar and naive human challenge infections. Am J Trop Med Hyg 2017; 97:1540–50.
    1. Howes RE, Reiner RC Jr, Battle KE, et al. . Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis 2015; 9:e0004222.
    1. Debo GW, Kassa DH. Prevalence of malaria and associated factors in Benna Tsemay district of pastoralist community, southern Ethiopia. Trop Dis Travel Med Vaccines 2016; 2:16.
    1. Golassa L, White MT. Population-level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre, East Shoa Zone, Oromia, Ethiopia. Malar J 2017; 16:301.
    1. Daniels RF, Deme AB, Gomis JF, et al. . Evidence of non-Plasmodium falciparum malaria infection in Kédougou, Sénégal. Malar J 2017; 16:9.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit